Baricitinib + Cyclophosphamide

ApprovedActive

1 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Systemic Sclerosis

Conditions

Systemic Sclerosis

Trial Timeline

Mar 8, 2022 → Nov 12, 2026

NCT ID

NCT05300932

About Baricitinib + Cyclophosphamide

Baricitinib + Cyclophosphamide is a approved stage product being developed by Eli Lilly for Systemic Sclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT05300932. Target conditions include Systemic Sclerosis.

What happened to similar drugs?

9 of 20 similar drugs in Systemic Sclerosis were approved

Approved (9) Terminated (4) Active (8)

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅EfalizumabMerckApproved

✅AmbrisentanGilead SciencesApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05300932	Approved	Active	Mar 8, 2022	Nov 12, 2026	Systemic Sclerosis

Competing Products

20 competing products in Systemic Sclerosis

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 2	35
E6742	Eisai	Phase 1/2	32
KHK4827	Kyowa Kirin	Phase 1	29
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks	Eli Lilly	Phase 3	40